Bristol Myers Squibb has revealed that the U.S. Food and Drug Administration has given the green light to Breyanzi® (lisocabtagene maraleucel; liso-cel).

The European Commission has approved Bristol Myers Squibb's Opdivo® (nivolumab) combined with cisplatin and gemcitabine for first-line therapy in adults with unresectable or metastatic urothelial carcinoma.

Jazz Pharmaceuticals plc revealed that the U.S. Food and Drug Administration (FDA) has accepted and given Priority Review status to the Biologics License Application (BLA) for zanidatamab.

Full-Life Technologies Receives FDA IND Clearance for 225Ac-FL-020 to Treat Metastatic Castration-Resistant Prostate Cancer.

VBI Vaccines Releases New Tumor Response Results from Ongoing Phase 2b Study of VBI-1901 in Patients with Recurrent Glioblastoma.

CDR-Life Inc. has started enrolling participants for the Phase 1 clinical trial of CDR404, their leading candidate being developed as a targeted immunotherapy for the treatment of solid tumors.

LIB Therapeutics Shares Positive Phase 3 Lerodalcibep Results at 92nd European Atherosclerosis Society Congress.

Atara Biotherapeutics Presents Early Research on ATA3219, a CAR T Therapy Targeting CD19 for B-Cell Autoimmune Diseases, at ISCT 2024.

The partnership involves the commercialization and licensing of BAT2506, a biosimilar of Simponi® (golimumab).

Outlook Therapeutics® Gains European Commission Approval for Marketing LYTENAVA™ (bevacizumab gamma) to Treat Wet AMD.

The U.S. Food and Drug Administration has granted approval to Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of specific rare conditions.

In the TROPION-Lung01 Phase III trial, datopotamab deruxtecan significantly improved overall survival compared to chemotherapy in patients with advanced nonsquamous non-small cell lung cancer.